Editor’s Note: In the original video, a statement was inaccurately attributed. We regret the error OKLAHOMA CITY (KFOR) — ...

To inform clinicians on the best biologic agent for different populations of adults with severe asthma, 12 experts collaborated on a new clinical practice guideline published in CHEST, according to a ...

Real-world data from 2016 to 2025 highlight the changing landscape of biologic use and the growing preference for tezepelumab in asthma.

Among patients with moderate to severe atopic dermatitis, APG777 produced significant reductions in disease severity at 16 weeks.

Corticosteroid injections may be the most impactful nonoperative treatment modality in delaying total shoulder arthroplasty, according to results presented here. “From the patient perspective, steroid ...

Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and symptoms, and systemic corticosteroid use or surgery ...

CAMBRIDGE, Mass., Feb. 17, 2026 /PRNewswire/ -- Sanofi today announced the appointment of Manuela Buxo as Head of Specialty Care, effective March 1, 2026. Manuela will succeed Brian Foard, who has ...

If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment TARRYTOWN, N ...

--Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the U.S. Food and Drug Administration has approved Dupixent ® for the treatment of adult and pediatric patients aged 6 years and older ...

If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment CSU is a ...